Murphy Sean
SEC CIK 1685042 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | Dir | 124.0K | $157.2K | — | 5 | 2024-02-12 | 2025-05-19 |
Most active insiders at TLSI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Stansky Michael P | Dir | $3.01M | — |
| 2 | Szela Mary T | CEO, Pres, Dir | $227.8K | $79.4K |
| 3 | Wahlstrom Mats | Dir | $151.8K | — |
| 4 | Valle William | Dir | $125.0K | — |
| 5 | Gordon Gary B. | Dir | $64.6K | — |
| 6 | Patience David | CFO | $32.2K | — |
| 7 | Marshak Richard | Chief Commercial Off | — | $15.7K |
| 8 | Stevens Jennifer | Chief Regulatory Off | — | $14.5K |
| 9 | Devlin Jodi | Chief of Clinical Ops | — | $13.2K |
| 10 | Cox Bryan F. | Chief of Research | — | $13.1K |
Murphy Sean made no open-market trades at TLSI in the last 12 months.
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-21 | 2025-05-19 | TLSI | TriSalus Life Sciences, Inc. | Murphy Sean | Dir | A - Grant | $5.18 | +44.9K | 124.0K | +57% | +$232.5K | |
| 2025-02-19 | 2025-02-18 | TLSI | TriSalus Life Sciences, Inc. | Murphy Sean | Chief Manuf, Strategy, Bus Dev, Dir | A - Grant | $0.00 | +15.8K | 79.1K | +25% | $0 | |
| DMI | 2025-01-29 | 2025-01-27+ | TLSI | TriSalus Life Sciences, Inc. | Murphy Sean | Chief Manuf, Strategy, Bus Dev, Dir | P - Purchase | $5.24 | +30.0K | 197.7K | +18% | +$157.2K |
| D | 2025-01-29 | 2025-01-27 | TLSI | TriSalus Life Sciences, Inc. | Murphy Sean | Chief Manuf, Strategy, Bus Dev, Dir | A - Grant | $0.00 | +12.5K | 63.3K | +25% | $0 |
| D | 2024-02-14 | 2024-02-12 | TLSI | TriSalus Life Sciences, Inc. | Murphy Sean | CFO, Dir | A - Grant | $0.00 | +34.1K | 50.8K | +205% | $0 |
Purchase Sale Sale after option exercise All abbreviations